Menlo Therapeutics Inc. (MNLO): Price and Financial Metrics
MNLO Price/Volume Stats
|Current price||$1.35||52-week high||$7.48|
|Prev. close||$1.38||52-week low||$1.00|
|Day high||$1.39||Avg. volume||2,817,431|
|50-day MA||$1.63||Dividend yield||N/A|
|200-day MA||$2.95||Market Cap||226.38M|
MNLO Stock Price Chart Interactive Chart >
Menlo Therapeutics Inc. (MNLO) Company Bio
Menlo Therapeutics Inc., a biopharmaceutical company, focuses on the development and commercialization of serlopitant for the treatment of pruritus associated with dermatologic conditions in the United States. The company has completed Phase II clinical trials in pruritus associated with prurigo nodularis. It is also developing products that are in Phase II clinical trials in pruritus associated with psoriasis and atopic dermatitis, and refractory chronic cough. The company was formerly known as Tigercat Pharma, Inc. and changed its name to Menlo Therapeutics Inc. in May 2016. Menlo Therapeutics Inc. was founded in 2011 and is based in Redwood City, California.
MNLO Latest News Stream
|Loading, please wait...|
MNLO Latest Social Stream
View Full MNLO Social Stream
Latest MNLO News From Around the Web
Below are the latest news stories about Menlo Therapeutics Inc that investors may wish to consider to help them evaluate MNLO as an investment opportunity.
A look at the shareholders of Menlo Therapeutics Inc. (NASDAQ:MNLO) can tell us which group is most powerful...
VYNE Therapeutics (formerly Menlo Therapeutics) to Present at the Cantor Fitzgerald and H.C. Wainwright Investment Conferences in September
BRIDGEWATER, N.J., Sept. 09, 2020 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that David Domzalski, Chief Executive Officer, will present at the upcoming H.C. Wainwright 22nd Annual Global Investment Conference and the Cantor Fitzgerald Virtual Global Healthcare Conference. H.C. Wainwright Annual Global Investment Conference Date:September 14 Time:2:30pm Eastern Time Webcast:https://wsw.com/webcast/hcw7/vyne/1630674 Cantor Fitzgerald Virtual Global Healthcare Conference Date:September 16 Time:10:00am Eastern Time Webcast:https://www.webcaster4.com/Webcast/Page/2495/37311 The Cantor Fitzgerald presentation will take the form of a “Fireside Chat” with analyst Louise Chen.About VYNE Therapeutics Inc. VYNE Thera...
VYNE Therapeutics Inc. (Nasdaq: VYNE) ("VYNE" or the "Company") today completed its previously announced corporate name change from Menlo Therapeutics Inc. to VYNE Therapeutics Inc. and the change of its ticker symbol from "MNLO" to "VYNE". The name and ticker symbol changes are effective as of the opening of trading today, September 8, 2020.
Company will commence trading under new ticker “VYNE” on September 8, 2020 Company to ring Nasdaq Closing Bell on September 8BRIDGEWATER, N.J., Sept. 02, 2020 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (Nasdaq: MNLO) (“Menlo” or the “Company”) announced today it is changing its corporate name to VYNE Therapeutics Inc. (“VYNE Therapeutics”). In connection with the name change, the Company’s common stock will begin trading under a new ticker symbol “VYNE”. The name and ticker change will be effective at the opening of trading, Tuesday, September 8, 2020. In addition, VYNE Therapeutics will ring the Nasdaq closing bell on September 8, at 4:00 PM ET. “Our new corporate branding, VYNE Therapeutics, reflects an evolution of our business which combines the strengths and traditions of our ...
Menlo Therapeutics Inc. (MNLO) Q2 2020 Earnings Conference Call August 6, 2020 8:30 AM ET Company Participants Michael Wood - LifeSci Advisors David Domzalski - Chief Executive Officer Matthew Wiley - Chief Commercial Officer Andrew Saik - Chief Financial Officer Conference Call Participants Carvey Leung - Cantor Fitzgerald Sadia Rahman...
MNLO Price Returns